Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: U-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity

Cancer Research

Volumn 69, Issue 6, 2009, Pages 2461-2470

  Nikolova, Dessislava A ^a   Asangani, Irfan A ^a   Nelson, Laura D ^c   Hughes, Dennis P M ^c   Siwak, Doris R ^c   Mills, Gordon R ^c   Harms, Andrea ^a   Buchholz, Erika ^b   Pilz, Lothar R ^a   Manegold, Christian ^b   Allgayer, Heike ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR JUND; UROKINASE RECEPTOR; UVOMORULIN; ANTINEOPLASTIC AGENT; CADHERIN; EPIDERMAL GROWTH FACTOR; MONOCLONAL ANTIBODY; PROTEIN C JUN; TUMOR MARKER;

ANIMAL CELL; ARTICLE; CANCER INVASION; CANCER TISSUE; CELL LINE; CELL PROLIFERATION; CHICK EMBRYO; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; EMBRYO; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; GENE EXPRESSION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CHICK EMBRYO; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NEOPLASM METASTASIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TUMOR MARKERS, BIOLOGICAL;

EID: 65549083563     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3236     Document Type: Article

References (50)

1. Jemal A, Murray T, Samuels A, Ghafor A, Ward E, Thun MJ, Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
3. Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer in the elderly, J Clin Oncol 2007;25:1898-907.
4. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Kon-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26:983-94.
5. Pavelic K, Banjac Z, Pavelic J, Spaventi S. Evidence for a role of EGF receptor In the progression of human lung carcinoma. Anticancer Res 1993;13:1133-7.
6. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network; receptor heterodimerlzation In development and cancer. EMBO J 2000;19:3159-7.
7. Schlesslnger J. Cell signalling by receptor tyrosine kinases. Cell 2000;103:211-25.
8. Cunningham D, Humblet Y, Siena S, et al. Cetuximab Monotherapy and Cetuximab plus irinotecan in irino-tecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
9. Hanna N, Lilenbaum R, Ansari R, et al. Phase II Trial of Cetuximab in patients with previously treated non- small-cell lung cancer. J Clin Oncol 2006;24:5253-8.
10. Raben D, Helfrich B, Chan DC, et al. The effect of Cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005;11:795-805.
11. Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinopmas after epidermal growth factor receptor blockade. Mol Cancer Res 2002;1:507-14.
12. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007;13:1552-61.
13. Morgensztern D, Govindan R. Is there a role for cetuximab in non small cell lung cancer? Clin Cancer Res 2007;13:4602-5.
14. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008;34:22-36.
15. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205-22.
16. Beyer BC, Heiss MM, Simon EH, et al. Urokinase system expression in gastric carcinoma: prognostic Impact In an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer 2006;106:1026-35.
17. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science 1996;273:1551-5.
18. Resnati M, Guttinger M, Valcamonlca S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996; 15:1572-82.
19. Hasegawa T, Sorensen L, Dohi M, Rao NV, Hoidal JR, Marshall BC. Induction of urokinase-type plasminogen activator receptor by IL-1 β Am J Respir Cell Mol Biol 1997;16:683-92.
20. Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002;1:445-57.
21. Jo M, Thomas KS, O'Donnell M, Gonias SL. Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor, J Biol Chem 2003;278:1642-6.
22. Leupold JH, Asangani I, Maurer GD, Lengyel E, Post S, Allgayer H. src induces urokinase receptor gene expression and invasion/intravasation via activator protein-l/p-c-Jun in colorectal cancer. Mol Cancer Res 2007;5:485-96.
23. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86.
24. Tibes R, Qiu Y, Lu Y, et al. Reverse phase protein array; validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006;5:2512-21.
25. Hu J, He X, Baggerly KA, Coombes KR, Hennessy BTJ, Mills GB. Non-parametric quantification of protein lysate arrays. Bioinformatics 2007;23:1986-94.
26. Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 2003;100:14229-34.
27. Asangani IA, Rasheed SA, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downre-gulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2007;27:2128-36.
28. Zijlstra A, Mellor R, Panzarella G, et al. A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res 2002;62:7083-92.
29. Mudduluru G, Medved F, Grobholz R, et al. Loss of programmed cell death 4 expression marks adenoma- carcinoma transition, correlates Inversely with phos-phorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer 2007;110:1697-707.
30. Jo M, Thomas KS, Marozkina N, et al. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator, J Biol Chem 2005;280:17449-57.
31. Lund LR, Ellis V Ronne TE, Fyke C, Dano K, Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem J 1995;310: 345-52.
32. Karin M. The regulation of AP-lactivity by mitogen-activated protein kinases. Philos Trans R Soc Lond B Biol Sci 1996;351:127-34.
33. Wang Y, Dang j, Wang H, Allgayer H, Murrell GAC, Boyd D, Identification of a novel nuclear factor-κB sequence involved expression of urokinase-type plasminogen activator receptor. Eur J Biochem 2000;267:3248-54.
34. Van der Wurff AA, ten Kate J, van der Linden EP, Dinjens WN, Arends JW, Bosnian FT, L-CAM expression in normal, premalignant and malignant colon mucosa, J Pathol 1992;168:287-91.
35. Nicholl SM, Roztocil E, Davies MG. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor, J Vase Surg 2005;41:672-81.
36. Hattori Y, Suzuki M, HarottI S, Kasai K, Vascular smooth muscle cell activation by glycated albumin (amadori adducts). Hypertension 2002;39:22-8.
37. Bhattacharya A, Lakka SS, Mohanam S, Boyd D, Rao JS. Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines. Clin Cancer Res 2001;7:267-76,
38. Eickelberg O, Pansky A, Mussmann R, et al. Transforming growth factor b1 Induces interleukin-6 expression via acting protein-1 consisting of junD homodimers in primary human lung fibroblasts, J Biol Chem 1999;274:12933-8.
39. Papo K, Seger D, Makovitzki A, et al. Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Res 2006;66:5371-8.
40. Paez JG, Jamie PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
41. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
42. Steiner P, Joynes C, Bassi R, et al. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res 2007;13:1540-5.
43. Doody JF, Wang Y, Patel SN, et al. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers, Mol Cancer Ther 2007;6:2642-51.
44. Raben D, Helfrich B, Chan DC, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005;11:795-805.
45. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005;65:226-35.
46. Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome In non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008;26:3351-7.
47. Weihua Z, Tsan R, Huang W, et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008;13:385-93.
48. Moustafa AEA, Yansouni C, Alaoui-Jamli MA, O'Connor-MeCourt M. lip-regulation of E-cadherin by an antl-epidermal growth factor receptor monoclonal antibody in lung cancer cell lines, Clin Cancer Res 1999;5:681-6.
49. Black PC, Brown GA, Inamoto T, et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008;14:1478-86.
50. Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66:944-50.